Significance of FEV3/FEV6 in Recognition of Early Airway Disease in Smokers at Risk of Development of COPD
Authors:
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- NIH
- Sunovion
- National Heart, Lung, and Blood Institute (HHSN268200900017C, U01 HL137880, U24 HL141762)
- Theravance Biopharma US
- Boehringer Ingelheim
- Bayer Fund
- GlaxoSmithKline
- Bellerophon Therapeutics
- Forest Research Institute
- Takeda Pharmaceutical Company
- COPD Foundation
This publication has 48 references indexed in Scilit:
- Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS): Table 1Thorax, 2013
- Pre- and post-bronchodilator lung function as predictors of mortality in the Lung Health StudyRespiratory Research, 2011
- Small-Airway Obstruction and Emphysema in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2011
- Clinical and Radiographic Predictors of GOLD–Unclassified Smokers in the COPDGene StudyAmerican Journal of Respiratory and Critical Care Medicine, 2011
- The role of small airways in obstructive airway diseasesEuropean Respiratory Review, 2011
- Should forced expiratory volume in six seconds replace forced vital capacity to detect airway obstruction?European Respiratory Journal, 2006
- Standardisation of spirometryEuropean Respiratory Journal, 2005
- The Nature of Small-Airway Obstruction in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2004
- Diagnosis of Airflow Limitation Combined With Smoking Cessation Advice Increases Stop-Smoking RateaChest, 2003
- The Relations between Structural Changes in Small Airways and Pulmonary-Function TestsNew England Journal of Medicine, 1978